B+
Bull case
30%
Probability
Target price
$211.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
BCPC
BalchemBNasdaq / Materials
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$190.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$153.00
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-26
Recent news sentiment (30D)
+20.7
Positive
Company
-
Unavailable
Macro
+20.7
Positive
Pulse
-
Unavailable
Weekly research (10D)
-24.0
Negative
Sentiment proxy
+65.1
Score
AI commentary
The company release and stored call excerpt are favorable, but the consensus beat is modest under one provider and EPS estimates differ across sources. The packet's October 23 close was $177; a dependable post-release return and whether the reaction held were not established. Post-print analyst revisions remain unconfirmed as of October 26, so unavailable signals should not be read as positive. Sentiment fields without verified coverage are set to zero as unavailable placeholders, not observed neutral readings. [#SEC-8K-2026-10-23] [#EARNINGS-TRANSCRIPT-2026Q3]
RankAlpha Sentiment Codex - 2026-10-26
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-30catalystPost-earnings digestionMedium impact
Balchem reported Q3 sales of $290.7 million, up 8.6% year over year, adjusted EPS of $1.57, and adjusted EBITDA of $80.3 million, up 12.4%. The SEC-filed earnings exhibit confirms growth across all three segments. One consensus source shows a modest beat against $1.54 EPS and $289.25 million revenue estimates; consensus figures vary by provider. Further price response is uncertain. [#8-K-2026-10-23] [#SEC-8K-2026-10-23] Earnings Whispers
2027-02-28eventTest of broad-based growth and cash conversionMedium impact
The next operating update can test whether Q3's segment-wide sales and operating-earnings growth persists. Q3 operating cash flow was $69.8 million and free cash flow was $57.9 million; these are a strong starting point, not a forecast. The date is an estimated review window, not an announced reporting date. [#SEC-8K-2026-10-23] [#EARNINGS-TRANSCRIPT-2026Q3]
2027-10-23catalystConversion of nutrition innovation into sustained salesHigh impact
Management cited demand for specialty nutrients and planned to showcase science-backed Human Nutrition & Health products at SupplySide Global. Commercial adoption and timing remain unquantified, making this a lower-confidence longer-term catalyst. [#SEC-8K-2026-10-23] [#EARNINGS-TRANSCRIPT-2026Q3]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-26 • Updated nightlySource: Internal modelMethodology